Loading
Antelope Surgical Solutions makes small molecules that stick to prostate cancer cells and glow during surgery, so the surgeon can see where the tumour ends; the same molecule is designed to carry a radioactive label for scans or treatment.
Antelope Surgical Solutions, Inc. is a New York City clinical-stage radiopharmaceutical company founded in 2020, according to the company, developing multimodal small molecules for radioligand therapy, PET imaging and fluorescence-guided surgery. It states that it has built a GMP manufacturing facility with robotic high-throughput synthesis and received its first FDA IND clearance for its lead agent. AS1986NS is a fluorescent PSMA-targeting agent in a single-arm, blinded histopathology trial in men with prostate cancer (NCT06906471). Its first registered cancer trial, NCT06906471, was posted on ClinicalTrials.gov in April 2025.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares PSMA, Radioligand therapy (beta emitters), Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/